Previous symbols: GLNS.
GLUL (glutamate-ammonia ligase) is named by 1 disorder entry.
In the ingested ai-gene-review snapshot, GLUL's core molecular functions are ATP binding; glutamine synthetase activity; and protein-cysteine S-palmitoyltransferase activity, acting in L-glutamine biosynthetic process; intracellular ammonium homeostasis; protein palmitoylation; and regulation of endothelial cell migration. The upstream review is being revised to keep glutamine synthetase activity as the single core function, treating ATP binding as part of that reaction and the palmitoyltransferase activity as a non-core moonlighting role; this page will change when the ingest is refreshed.
The one entry that names GLUL, Developmental and Epileptic Encephalopathy 116, types it causative with a de novo origin and a gain of function impact. The gene sits on the node GLUL Start-Loss and 5' UTR Splice Variants. The variants let the enzyme escape its normal glutamine-triggered degradation, so the entry marks glutamine synthetase activity as gained rather than lost.
ClinGen classifies GLUL for 2 diseases. No dismech entry yet curates the recessive deficiency ClinGen classifies, congenital brain dysgenesis due to glutamine synthetase deficiency, which is the loss-of-function counterpart of the entry above.
Underlined values are claims re-computed from the knowledge base each time this page is built. The tables below are the source of truth.
ai-gene-review has this gene at status INITIALIZED; the description is shown only once the review is complete. Read the draft upstream.
Relationship is the entry's genetic[].relationship_type. untyped means the entry has a genetic record for the gene but does not type it; its free-text association is shown instead.
| Disorder | Relationship | Where the gene appears |
|---|---|---|
| Developmental and Epileptic Encephalopathy 116 | causative de novo gain of function |
mechanism: GLUL Start-Loss and 5' UTR Splice Variants; Unregulated Glutamine Synthetase Activity in Astrocytes and Glial Progenitors
|
An entry matches when ClinGen's MONDO disease is the entry's own disease term, a subtype term, or an exact-match mapping. An amber status marks an entry ClinGen supports the gene for (Definitive, Strong or Moderate) whose own record does not type it. A Limited, Disputed or Refuted tier on such an entry is not a gap.
| ClinGen disease | MOI | Classification | dismech entry |
|---|---|---|---|
| congenital brain dysgenesis due to glutamine synthetase deficiency MONDO:0012393 | AR | Moderate 2024-12-13 |
no dismech entry |
| genetic developmental and epileptic encephalopathy MONDO:0100062 | AD | Moderate 2025-01-07 |
Identity from HGNC (snapshot 2026-10-01). Page layers are described in the gene pages documentation.